Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma

Proteasome inhibition is an effective treatment strategy for multiple myeloma. With improving survival, attention is increasingly focusing on ease of administration and toxicity profile. Ixazomib is an investigational, orally bioavailable 20S proteasome inhibitor. Sixty patients with relapsed and/or...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood
Auteurs principaux: Kumar, Shaji K., Bensinger, William I., Zimmerman, Todd M., Reeder, Craig B., Berenson, James R., Berg, Deborah, Hui, Ai-Min, Gupta, Neeraj, Di Bacco, Alessandra, Yu, Jiang, Shou, Yaping, Niesvizky, Ruben
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2014
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4468583/
https://ncbi.nlm.nih.gov/pubmed/24904120
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-01-548941
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires